Egr-1: A Target for Scleroderma Therapy PDF Print E-mail
Monday, 26 April 2010 15:10
Two separate research groups funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) have discovered that the molecule EGR-1 (early growth response 1), which regulates gene expression, plays a central role in the development of fibrosis, a condition in which organ-supporting tissue becomes thick, hard, and rigid, hindering normal tissue and organ function. Controlling EGR-1, say the scientists, could be a potential therapy for such disorders as Scleroderma and pulmonary fibrosis. Their findings have been reported in the American Journal of Pathology.

Fibrosis is a disorder of the extracellular matrix, the mesh of proteins like collagen that makes up the body’s connective tissue. It is a factor in scleroderma, among other diseases, and can affect many of the body’s organs, including the lungs, liver, and skin. Its consequences can be devastating, even leading to death. Recent research has shown that cells in fibrotic tissue receive the wrong molecular signals, causing too many extracellular proteins to be made. One possible way to approach the fibrosis problem, scientists say, might be to try to interrupt such signals at critical points in the cellular pathways that they travel.

The two research groups, headed by Carol Feghali-Bostwick, Ph.D., at the University of Pittsburgh School of Medicine and John Varga, M.D ., at Northwestern University’s Feinberg School of Medicine, took separate approaches in discovering the importance of EGR-1. The University of Pittsburgh group induced fibrosis in mouse and human fibroblasts (cells that make up the extracellular matrix) by utilizing a signaling protein called IGFBP-5 (insulin-like growth factor binding protein 5). The Northwestern team administered the antibiotic bleomycin to induce scleroderma in mice. Both research teams found that the experimentally produced fibrosis was associated with abnormally elevated EGR-1 activity.

Furthermore, when they produced fibrosis in cells or in mice lacking EGR-1, the amounts of fibrosis were dramatically reduced. In further support of the findings, the Pittsburgh group found that EGR-1 levels were higher in lung tissues and fibroblasts of people with pulmonary fibrosis compared to controls. EGR-1, concluded the scientists, appears to be essential for the development of fibrosis, making it a potential target for therapy. The two studies also showed that independent signaling pathways, such as those for IGFBP-5 and bleomycin, both converge on EGR-1 to create fibrosis.

Fibrosis is a common disorder and a serious complication of many diseases. It is still considered hard to treat, with no currently approved therapies. Because the understanding of fibrosis is a major unmet medical need, any fresh insights into the disease process might open the door for novel therapies.

Source: 7th Space
 
More articles :

» Anticoagulation of Systemic Sclerosis Patients In Question

Australia is in a state of ‘clinical equipoise’ over whether to anticoagulate systemic sclerosis patients with pulmonary hypertension, experts say. And with observational studies showing the treatment is associated with a  fivefold...

» Study Suggests Systemic Sclerosis Is an Independent Risk Factor for Atherosclerosis

A new study by researchers in Hong Kong suggests that is an independent determinant for moderate to severe coronary calcification or . Conventional cardiovascular risk factors such as age and hypertension predispose patients with systemic sclerosis...

» Greater Global Cooperation and Collaboration in Scleroderma Research Required

Greater global cooperation and collaboration among Scleroderma researchers and clinicians would be all that is required to fuel a drive toward important discoveries and optimize outcomes for patients with this chronic, progressive, and often...

» Passing Down Gene Causing Infections and Autoimmune Diseases

New evidence points to why genes that make us susceptible to infections and autoimmune diseases continue to be passed down instead of being eradicated from the gene pool. (NSF) reports that biologists conducting research funded by the NSF and the ...

» Systemic Sclerosis (Scleroderma)

Panayiotis G. Vlachoyiannopoulos1November 2001Systemic sclerosis (SSc) is an autoimmune systemic disease characterized by small vessel involvement that leads to tissue ischemia and fibroblast stimulation resulting in accumulation of collagen...

» We Need Your Help!

Today, the Scleroderma Care Foundation embarks upon a mission of vital importance, and we are counting on your help. One of our dearest patients and friend, , is on the verge of Renal or and we are seeking out a qualified kidney donor. Currently,...

Comments  

 
+1 #2 Nia 2012-09-16 23:51
i hve sd, very grateful for this research. wouldnt be suprised if there's a vaccine for autoimmune doseases in the not too distant future.
Report to administrator
 
 
+1 #1 Nia 2012-09-16 23:50
Quote:
exciting!
didnt know SD could be induced with an antibiotic...
Report to administrator